New Delhi: After Thrombosis with Thrombocytopenia Syndrome (TTS), it has now been found that British-Swedish pharma giant AstraZeneca’s COVID-19 vaccine, made in collaboration with Oxford University can raise the risk of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) , a rare but fatal blood clotting disorder, claimed researchers. While not new, VITT emerged as a new disease following adenovirus vector-based Oxford-AstraZeneca vaccine sold as Covishield in India and Vaxzevria in Europe at the height of the COVID pandemic in 2021, IANS reported.
“An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4)” was found as the reason for VITT.
In separate research in 2023, scientists from Canada, North America, Germany and Italy described a virtually identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.
Bhubaneswar: A day after indictment of Gautam Adani in the US in a fraud scheme,…
New York: US President-elect Donald Trump on Thursday nominated Pam Bondi, the former attorney general…
Koraput: Police on Friday claimed to have busted a ganja smuggling racket being carried out…
New York: The recent indictment of top executives of Adani Group, including its chairperson Gautam…
Bhubaneswar: The result of the Odisha Teacher's Eligibility Test (OTET)-2024 was announced on Friday. The…
Bhubaneswar: An attempt for an amicable settlement of the dispute, involving Ollywood director Bobby Islam…
Bhubaneswar: Dense fog occurred at one or two places in Sundargarh and shallow to moderate…
Mumbai: The Mumbai Police crime branch revealed that an accused in the Baba Siddiqui murder…